Loading...

SUVENPHAR Suven Pharmaceuticals Ltd Major expansion or diversification plans Announcement

Svn

SVNP

Suven Pharmaceuticals Ltd

(SUVENPHAR)

2025 Announcement

Summary

Summary

Newspaper Publication

USFDA Inspection Update

Share Sale Disclosure

USFDA Inspection Complete

Investor Meeting

Annual Report Update

Share Sale Notice

AGM Notice Publication

Credit Rating Upgrade

Earnings Call Transcript

Financial Results Publication

USFDA Inspection Completed

Conference Call Audio

Major Investment Announcement

USD 10M Investment

Corporate Guarantee Issued

New CEO Appointment

Management Change

Investor Conference Call

Investor Conference Call

Regulatory Disclosure

Compliance Certificate

Appointment of Auditors

Investor Meeting

Earnings Call Transcript

Financial Results Published

Annual Compliance Report

Credit Rating Update

Conference Call Audio

Financial Results

Investor Presentation

Investor Meeting

FDA Inspection Report

Investor Conference Call

Share Allotment

Merger Effective Date

Merger Approval

Compliance Certificate

Cautionary Email

Cautionary Email Received

Management Change

Investor Meetings

Credit Rating Update

Investor Meet Notice

Earnings Call Transcript

Financial Results Published

Conference Call Audio

Investor Presentation

Q3 Earnings Report

Investor Meetings

Conference Call Update

Conference Call Scheduled

Investor Presentation

Compliance Certificate

Acquisition Update

Acquisition Announcement

Conference Call Audio

Investor Conference Call

Stake Acquisition

NJ Bio Acquisition

Acquisition Announcement

Investor Meeting

Investor Meeting Notice

Credit Rating Update

Postal Ballot Notice

Investor Meeting

Earnings Call Summary

Financial Results Released

Earnings Call Recording

Q2 Financial Results

Investor Presentation

Director Changes

Investor Meetings

Investor Call Scheduled

NCLT Meeting Notice

Merger Approval

Regulatory Update

Management Change

Investor Meeting

New Chairman Appointment

Management Change

Company Petition Notice

Investor Meeting

FDA Inspection Update

Investor Meeting

Amalgamation Update

Credit Rating Update

Management Appointment

Investor Meeting

Investor Meeting

Earnings Call Transcript

Financial Results Published

Financial and Management Ch...

Appointment of Company Secr...

Conference Call Announcement

Observation Approval

Certificate Submission

Newspaper Advertisement

US FDA Inspection

Annual Meeting Announcement

Acquisition Update

Appointment of Statutory Au...

Acquisition Announcement

Conference Call Outcome

Amalgamation Approval

Acquisition of Sapala Organ...

Analyst Meeting Participation

Transcript Release

Analyst Meet Intimation

Newspaper Advertisement

Equity Investment Approval

Conference Call Rescheduled

Investor Meeting

Compliance Report Submission

Conference Call Postponement

Board Meeting Update

Conference Call

Certificate Submission

Compliance Certificate Subm...

Compliance Certificate Subm...

Change of Address

Analyst Meeting

Merger Proposal

Conference Call Outcome

Conference Call

Merger Presentation

Merger Announcement

Amalgamation Approval

Stock Options Allotment

FDA Inspection Passing

Publication of Financial Re...

Investor Presentation

Investor Conference

Reclassification Approval

Notice of Postal Ballot

Compliance Certificate

Resignation of CFO

Board Meeting Outcome

Resignation of Senior Manag...

Newspaper Advertisement

AGM newspaper publication

Reclassification of Promote...

Newspaper Publication

Newspaper Advertisement

Post Offer Advertisement

Change in Directorate

Earnings Presentation

Investor Conference

Submission of Recommendations

Acquisition Offer

Certificate Submission

Acquisition of Suven Pharma

Change in Control and New D...

Change in Management Control

Acquisition Approval

Financial Statements

Financial Statements

Conference call for Q1FY24 ...

Earnings Call Transcript

Financial Results Publication

Corporate Governance Compli...

External Links:

Data:

Cohance Lifesciences Ltd announced a USD 10 million investment to expand its bioconjugation capabilities at NJ Bio, Princeton, enhancing its Antibody-Drug Conjugate (ADC) solutions. This update follows the event which occurred on August 12, 2025, and the new facility is expected to be operational by the end of Q4FY26.

AI Assistant

Suven Pharmaceuticals Ltd

2025

Announcement

Find Answers

Ask about any part of the document to get insights, explanations, or key details.